Nanobactérie
Side effects; Operation theatre required; General anesthesia needed; Prostate malfunction/removal; Need of expensive, big, dedicated equipment (for radiotherapy or robotic surgery); Expensive; Lack of full efficacy; Complex to implement. Our innovation Breakthrough in cancer therapy AlphaOnco is pioneering a novel focal therapy for intermediate to advanced prostate cancer*, leveraging mild ultrasound-induced hyperthermia in combination with natural iron oxide nanoparticles, known as magnetosomes
Basic Information
- Category: company
- Website: https://www.nanobacterie.fr/
Documented Facts
- Inception (Wikidata): 2008 (Source 3: Wikidata Q112124919, revision 1665925334)
- Legal form (Wikidata; date unspecified): société à responsabilité limitée (Source 3: Wikidata Q112124919, revision 1665925334; Source 4: Wikidata label: Q15091621, revision 2550157400)
- Headquarters location (Wikidata; date unspecified): Orsay (Source 3: Wikidata Q112124919, revision 1665925334; Source 5: Wikidata label: Q372281, revision 2527468079)
- Country (Wikidata; date unspecified): France (Source 3: Wikidata Q112124919, revision 1665925334; Source 6: Wikidata label: Q142, revision 2555583941)
Evidence and Sources
- Nanobactérie — Official Site (official)
- Nanobactérie on linkedin (social)
- Wikidata Q112124919, revision 1665925334 (knowledge-base)
- Wikidata label: Q15091621, revision 2550157400 (knowledge-base)
- Wikidata label: Q372281, revision 2527468079 (knowledge-base)
- Wikidata label: Q142, revision 2555583941 (knowledge-base)
Citation Guidance
Explore company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Nanobactérie.
- Canonical profile: https://brandsource.ai/brands/nanobacterie
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/nanobacterie/json-ld
- Citation profile API: https://brandsource.ai/api/brands/nanobacterie/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Side effects; Operation theatre required; General anesthesia needed; Prostate malfunction/removal; Need of expensive, big, dedicated equipment (for radiotherapy or robotic surgery); Expensive; Lack of full efficacy; Complex to implement. Our innovation Breakthrough in cancer therapy AlphaOnco is pioneering a novel focal therapy for intermediate to advanced prostate cancer*, leveraging mild ultrasound-induced hyperthermia in combination with natural iron oxide nanoparticles, known as magnetosomes
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 5 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.